BMC Cancer (May 2017)

First case of B ALL with KMT2A-MAML2 rearrangement: a case report

  • Estelle Menu,
  • Nathalie Beaufils,
  • Fabrice Usseglio,
  • Estelle Balducci,
  • Marina Lafage Pochitaloff,
  • Regis Costello,
  • Jean Gabert

DOI
https://doi.org/10.1186/s12885-017-3368-4
Journal volume & issue
Vol. 17, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Background A large number of chromosomal translocations of the human KMT2A gene, better known as the MLL gene, have so far been characterized. Genetic rearrangements involving KMT2A gene are frequently involved in lymphoid, myeloid and mixed lineage leukemia. One of its rare fusion partners, the mastermind like 2 (MAML2) gene has been reported in four cases of myeloid neoplasms after chemotherapy so far: two acute myeloid leukemias (AML) and two myelodysplasic syndrome (MDS), and two cases of secondary T-cell acute lymphoblastic leukemia (T-ALL). Case presentation Here we report the case of a KMT2A - MAML2 fusion discovered by Next-Generation Sequencing (NGS) analysis in front of an inv11 (q21q23) present in a 47-year-old female previously treated for a sarcoma in 2014, who had a B acute lymphoid leukemia (B ALL). Conclusion It is, to our knowledge, the first case of B acute lymphoblastic leukemia with this fusion gene. At the molecular level, two rearrangements were detected using RNA sequencing juxtaposing exon 7 to exon 2 and exon 9 to intron 1–2 of the KMT2A and MAML2 genes respectively, and one rearrangement using Sanger sequencing juxtaposing exon 8 and exon 2.

Keywords